Research & Education

Evolution of Therapeutic Decision-Making for Advanced Squamous Cell Lung Cancer (SqCLC)

December 3, 2018 at 9:00PM EST - Recording Available
 Dr. David R. Gandara  

David R. Gandara, MD
Professor of Medicine Emeritus
Director, Thoracic Oncology
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center

 Ramaswamy Govindan, MD - Program Chair

Director, Section of Medical Oncology
Professor of Medicine
Anheuser-Busch Endowed Chair in Medical Oncology
Director, Section of Oncology
Washington University School of Medicine

 

Name of Reviewer(s): 

Ihsan Allobi, MD:

No Relevante Financial/Commercial relationships to Disclose.

Laurie Gaspar, MD: 

No Relevante Financial/Commercial Relationships to Disclose

Name of Planner(s): 

 

Carlos Ferreira-Nothing to Disclose

 Education Committee (Planner)

Fredericco Cappuzzo, MD

No relevant Financial/Commercial Relationships to Disclosed

Name of Activity: 

 

Evolution of Therapeutic Decision-Making for Advanced Squamous Cell Lung Cancer (SqCLC) 

Date of Activity:

 

December 3, 2018 at 9:00 PM EST 

Faculty/Speaker(s)Disclosure:

COI Resolution: Ensure a balanced discussion of alternative. Do not use trade names. Do not refer to company names or logos. Do not recommend therapies.

“All planning committee members’, reviewers, planners and faculty et al. identified conflicts of interest pertaining to this activity were resolved prior to the activity.”

Speaker: Dr. David R. Gandara 

Advisory Board: AstraZeneca, Boerhringer-Ingelheim, Celgene, CellMax, Genentech, Guardant Health, Inivata, IO Biotech, Lilly, Liquid Genomics, Merck, Samsung

Contracted/Support Research Grant: AstraZeneca, Bristol-Meyers Squibb, Merck, Novartis, Roche-Genentech

 Moderator: Ramaswamy Govindan, MD

Pfizer: Advisory Board, Celgene: Advisory Board, AztraZeneca: Advisory Board, INC Research: Consulting, AbbVie: Consulting, Advisory Board and Honorarium, MSK: Advisory Board, BMS, ROCHE, ABBVIE, CELGENE, AZ, MERCK: Honoraria.

Type of Activity:

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?

    No

If yes, please list:

About the Program:

Squamous cell and non-squamous cell lung cancer are largely different diseases biologically. Until recently, squamous cell lung cancer has remained an unmet need, as chemotherapy advances had plateaued and targeted therapy for oncogene-driven cancers had almost exclusively been relegated to adenocarcinoma subsets. However, in the last three years checkpoint immunotherapy has revolutionized the approach to squamous lung cancer, both in the 2nd line and now the 1st line setting. Additionally, uncommon subsets of oncogene-driven squamous cancers may be candidates for targeted therapy, such as those harboring HER family mutations.

OBJECTIVES:

After attending this activity learners will be able to:

OBJECTIVES

  • Create awareness of new treatment advances in the management of squamous cell lung cancer.
  • Discuss recent developments in the integration of Checkpoint inhibition immunotherapy for squamous cell lung cancer.
  • Identify potential new targeted therapy for uncommon subsets of oncogene-driven squamous cancers.

In this one hour presentation, Dr. Gandara will highlight new findings in the biology of squamous lung cancers leading to therapeutic advance. Following the presentation, there will be ample time for questions, comments and discussion with Dr.Gandara and Dr. Govindan.

DOWNLOAD RECORDING

Financial Commercial and Conflicts of Interest Disclosure Form

IASLC Guidelines For Individuals Planning and/or Presenting a IASLC CME Activity

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

CME INFORMATION:

DEFINITION OF A COMMERCIAL INTEREST: commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

DEFINITION OF CME

Continuing medical education consists of educational activities which serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession. The content of CME is that body of knowledge and skills generally recognized and accepted by the profession as within the basic medical sciences, the discipline of clinical medicine, and the provision of health care to the public.

Financial/Commercial Relationships DISCLOSURES

A conflict of interest (COI) is created and exists when individuals in a position to control the content of CME (or their spouses/partners) have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells or distributes health care goods or services consumed by, or used on, patients that benefits the individual in any financial amount and therefore may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds) or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership and other activities for which remuneration is received or expected. 

This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME Department assures that the planners/reviewers/authors/faculty/peer reviewers et al. conflicts of interest were identified, reviewed and resolved fromall individuals involved in the development or able to influence and control the content of this CME activity. The IASLC CME Department assures that disclosure is given prior to an educational activity being delivered to learners. Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from all IASLC CME activity presentations.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Committee and/or an independent reviewer. COI will be evaluated by the IASLC Board of Directors for fair balance, scientific objectivity of studies utilized in this activity and patient care recommendations. The IASLC CME Department is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

The intent of this disclosure is not to prevent a speaker with a relevant financial or other relationship from making the presentation, but rather to identify and resolve any conflicts of interest that may control the content of the activity. It is also intended that any potential conflict be identified openly so that the listeners have a full disclosure of the facts and may form their own judgments about the presentation. It remains for the audience to determine whether the speaker’s interests or relationships may influence the presentation with regard to exposition or conclusion.

All other faculty/contributors et al. have reported no commercial affiliation associated with this conference or intent to reference off-label/unapproved uses of products or devices in their presentations.

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

TARGET AUDIENCE

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

COMMERCIAL INTEREST INFLUENCE

Creators/presenters/planners et al. are not permitted to receive any direct remuneration or gifts or in-kind support from any commercial interest in relationship to this activity, nor should faculty be subject to direction from commercial interests regarding the content or delivery of their presentation.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Please complete the evaluation link provided to you after the activity. The certificate of credit will be ready for you to print or save for your records.

Attendees can now view IASLC Live webinars via their mobile device.  

Downloading of the Cisco WebEx Meetings app is required.

Once the app is installed on your device you will need to enter the event number for each session.

 Registration is required for all IASLC webinars.